One-time gene therapy could improve wet AMD
A Phase I/IIa trial suggests that a subretinal gene therapy…
A Phase I/IIa trial suggests that a subretinal gene therapy for wet age-related macular degeneration (wet AMD) could reduce the need for patients to receive anti-VEGF injections.